EKEiki Kikuchi

Eiki Kikuchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eiki Kikuchi has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan

    by Junichi Shimizu, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, et al.

    Pivotal phase 3 trials leading to the approvals of atezolizumab─chemotherapy combinations for non‐small cell and extensive‐stage small cell lung cancer (NSCLC and ES‐SCLC) had strict eligibility criteria. J‐TAIL‐2 was a prospective, observational study in Japan that evaluated atezolizumab regimens for advanced NSCLC/ES‐SCLC, including patients ineligible for global trials. The primary endpoint was 12‐month overall survival (OS); safety and efficacy in subgroups defined by age, ECOG PS and/or G8 score, and creatinine clearance were key secondary endpoints. As of February 3, 2023, 1217 patients were treated in clinical practice based on Japanese labeling/treatment guidelines. Patients received atezolizumab with either carboplatin and nab‐paclitaxel (atezo + CnP), carboplatin/cisplatin and pemetrexed (atezo + PP), or bevacizumab and carboplatin and paclitaxel (atezo + bev + CP) in the NSCLC cohort ( n = 814) or with carboplatin and etoposide (atezo + CE) in the ES‐SCLC cohort ( n = 403). Overall, 53.5% were ≥ 70 years old, and 11.8% had ECOG PS ≥ 2; median G8 scores were 13 (NSCLC cohort) and 12 (ES‐SCLC). Patients < 70 and ≥ 70 years had similar median (m)OS and progression‐free survival (mPFS) across treatment regimens. Patients with ECOG PS < 2 and G8 score ≥ median had the highest mOS/PFS vs. patients with ECOG PS ≥ 2 and G8 scoreTrial Registration: ClinicalTrials.gov : NCT04501497

  • Open Access

    Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2

    by Yasushi Goto, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Junichi Shimizu, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, et al.

    J‐TAIL‐2 evaluated the efficacy and safety of atezolizumab, an anti–programmed death‐ligand 1 (PD‐L1), plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in Japanese clinical practice, demonstrating comparable outcomes to those in the corresponding Phase 3 trials. Although PD‐L1 expression is predictive of atezolizumab efficacy in some settings, additional minimally invasive, blood‐based biomarkers are needed. This exploratory biomarker study included 359 J‐TAIL‐2 patients. The NSCLC cohort received atezolizumab combined with carboplatin and nab‐paclitaxel (CnP, n = 42), cisplatin/carboplatin and pemetrexed ( n = 72), or bevacizumab plus carboplatin and paclitaxel (bev + CP, n = 135). The ES‐SCLC cohort received atezolizumab plus carboplatin and etoposide ( n = 100). Approximately 560 cancer‐ or immune‐related proteins were evaluated using the Proximity Extension Assay from blood plasma collected at three timepoints: baseline, before the second atezolizumab dose, and at the onset of immune‐related adverse events (irAEs). Protein‐wise comparisons were made to evaluate significant changes ( P < 0.05 and > 0.5 log2 fold change) and linked to clinical outcomes reported in J‐TAIL‐2. IL‐6, MUC‐16, and KRT‐19 were associated with shorter progression‐free survival across multiple regimens. Granzyme A and B, immune activation markers, were elevated in responders who received atezolizumab + CnP and atezolizumab + bev + CP. High levels of baseline immune stimulation proteins were associated with irAEs across regimens. Protein expression changes were varied and regimen‐dependent in subgroup analyses including older patients and those with EGFR ‐mutant tumors. These data warrant further investigation across different cancer types and atezolizumab‐containing regimens to determine their relevance to efficacy and irAE occurrence of atezolizumab combination therapy. Trial Registration: ClinicalTrials.gov ID, NCT04501497 (J‐TAIL‐2) and NCT04818983 (biomarker study)


  • Open Access

    Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)

    by Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Ichiro Yoshino, et al.

    First‐line atezolizumab combination therapies were approved for the treatment of metastatic non‐small cell lung cancer (NSCLC) based on results from the global phase 3 trials IMpower130, IMpower132, and IMpower150. These trials reported 12‐month overall survival (OS) rates of 60%–67% with atezolizumab combination therapy. J‐TAIL‐2 (NCT04501497), a prospective, multicenter, observational study, evaluated atezolizumab combination therapy in routine clinical practice in Japan. Patients ≥ 20 years old with NSCLC received atezolizumab plus carboplatin and nab‐paclitaxel (atezo + CnP), atezolizumab plus carboplatin or cisplatin plus pemetrexed (atezo + PP), or atezolizumab plus bevacizumab plus carboplatin and paclitaxel (atezo + bev + CP) in clinical practice. The primary endpoint was the 12‐month OS rate. Secondary endpoints included OS, progression‐free survival, and subgroup analyses, including IMpower‐unlike (did not meet the main eligibility criteria of each IMpower trial) and IMpower‐like patients. In total, 814 patients were enrolled (atezo + CnP, n = 217; atezo + PP, n = 211; atezo + bev + CP, n = 386). The IMpower‐unlike group included patients with Eastern Cooperative Oncology Group performance status ≥ 2, autoimmune disease, or interstitial lung disease. Twelve‐month OS rates (95% confidence interval [CI]) were 62.9% (55.8–69.2), 72.1% (65.2–77.9), and 68.3% (63.2–72.9) with atezo + CnP, atezo + PP, and atezo + bev + CP, respectively. OS hazard ratios (95% CI) in the IMpower‐unlike vs. ‐like subgroups were 1.36 (0.91–2.05), 1.08 (0.70–1.68), and 1.49 (1.09–2.06), respectively. No new safety signals were observed. Real‐world efficacy and safety for each atezolizumab combination were comparable to those in the relevant IMpower trials.


  • Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer

    by Kosuke Tsuji, Eiki Kikuchi, Yuta Takashima, Tetsuaki Shoji, Hirofumi Takahashi, Shotaro Ito, Daisuke Morinaga, Masahiro Kashima, Makie Maeda, Hidenori Kitai, et al.

    Mitotic slippage, which enables cancer cells to bypass cell death by transitioning from mitosis to the G1 phase without undergoing normal cytokinesis, is one likely mechanism of paclitaxel (PTX) resistance. DNA double-strand breaks (DSBs) in the G1 phase are mainly repaired through non-homologous end joining (NHEJ). Therefore, inhibiting NHEJ could augment the PTX-induced cytotoxicity by impeding the repair of PTX-induced DSBs during the G1 phase following mitotic slippage. We aimed to evaluate the effects of NHEJ inhibition on mitotic slippage after PTX treatment in non-small cell lung cancer (NSCLC). H1299, A549, H1975, and H520 NSCLC cell lines were employed. In addition, A-196 and JQ1 were used as NHEJ inhibitors. H1299 cells were PTX-resistant and exhibited an increased frequency of mitotic slippage upon PTX treatment. NHEJ inhibitors significantly augmented the PTX-induced cytotoxicity, DSBs, and apoptosis in H1299 cells. The newly generated PTX-resistant cells were even more prone to mitotic slippage following PTX treatment and susceptible to the combined therapy. Docetaxel further demonstrated synergistic effects with the NHEJ inhibitor in PTX-resistant cells. NHEJ inhibition may overcome intrinsic or acquired PTX resistance resulting from mitotic slippage by synergistically increasing the cytotoxic effects of antimitotic drugs in NSCLC.


  • Open Access

    Supplementary Methods from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

    by Haikuo Zhang, Jun Qi, Jaime M. Reyes, Lewyn Li, Prakash K. Rao, Fugen Li, Charles Y. Lin, Jennifer A. Perry, Matthew A. Lawlor, Alexander Federation, et al.

  • Open Access

    Supplementary Table 3 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

    by Haikuo Zhang, Jun Qi, Jaime M. Reyes, Lewyn Li, Prakash K. Rao, Fugen Li, Charles Y. Lin, Jennifer A. Perry, Matthew A. Lawlor, Alexander Federation, et al.

  • Open Access

    Supplementary Methods from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

    by Haikuo Zhang, Jun Qi, Jaime M. Reyes, Lewyn Li, Prakash K. Rao, Fugen Li, Charles Y. Lin, Jennifer A. Perry, Matthew A. Lawlor, Alexander Federation, et al.

  • Open Access

    Supplementary Figures S1 - S5, Tables S1 - S2 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

    by Haikuo Zhang, Jun Qi, Jaime M. Reyes, Lewyn Li, Prakash K. Rao, Fugen Li, Charles Y. Lin, Jennifer A. Perry, Matthew A. Lawlor, Alexander Federation, et al.

  • Open Access

    Supplementary Figures S1 - S5, Tables S1 - S2 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

    by Haikuo Zhang, Jun Qi, Jaime M. Reyes, Lewyn Li, Prakash K. Rao, Fugen Li, Charles Y. Lin, Jennifer A. Perry, Matthew A. Lawlor, Alexander Federation, et al.

  • Open Access

    Supplementary Table 3 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

    by Haikuo Zhang, Jun Qi, Jaime M. Reyes, Lewyn Li, Prakash K. Rao, Fugen Li, Charles Y. Lin, Jennifer A. Perry, Matthew A. Lawlor, Alexander Federation, et al.